Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Hunan
Clinical trial register · China

Clinical Trials in Hunan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19212 matching records held by the registry are in this view. Synced 10 Nov 2026, 03:17 UTC
19212
Studies in scope
all four open statuses
11805
Recruiting now
open to new participants
2029
Lead sponsors
across recruiting studies
Top sites
Beijing 5582 Shanghai 3880 Guangzhou 3354 Hangzhou 1824 Wuhan 1342
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Shanghai Henlius Biotech3 RemeGen Co., Ltd.2 Brise Pharmaceuticals Co., Ltd.2 BioNTech SE1 Beijing BeneWill Technology Development Co., Ltd1
Site location
Beijing5582 Shanghai3880 Guangzhou3354 Hangzhou1824 Wuhan1342
All 625 locations
Target enrolment
to

Trials with a site in Hunan

32 of 19212 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as First-Line Treatment for Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations
NCT07829549Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations
DrugsRC148·Tislelizumab
RemeGen Co., Ltd.
Phase 3
540
Hunan
2026-09-30
Recruiting
Brise Pharmaceuticals Co., Ltd.
Phase 2/3
2,079
Shanxi, Inner Mongolia, Beijing, Anhui, Hebei, Jilin City, Hunan, Chongqing
2026-09-30
Not yet open
Brise Pharmaceuticals Co., Ltd.
Phase 3
1,000
Shanxi, Inner Mongolia, Beijing, Anhui, Hebei, Jilin City, Hunan, Chongqing
2026-09-30
Not yet open
Rongchang Pharmaceuticals Co., Ltd.
Phase 1/2
486
Beijing, Hunan, Zhejiang, Shandong, Shanghai, Shanxi, Tianjin
2026-09-15
Recruiting
Phase III Clinical Trial of Recombinant Respiratory Syncytial Virus Vaccine (CHO Cells)
NCT07860216Assessing the Effectiveness of Vaccines in Preventing Adult RSV-caused Lower Respiratory Tract Disease (LRTD)
DrugRecombinant respiratory syncytial virus vaccine
Beijing BeneWill Technology Development Co., Ltd
Phase 3
25,000
GuiZhou, Hebei, HuBei, HuNan, Shandong, Shanxi, Baoshan
2026-08-21
Recruiting
Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)
NCT07567625Acute Myocardial Infarction (AMI), ST-Segment Elevation Myocardial Infarction(STEMI), Non-ST-Segment Elevation Myocardial Infarction(NSTEMI)
Harbin Medical University
Not applicable
2,000
Harbin, Beijing, Cangzhou, Chengde, Chengdu, Dalian, Daqing, Hunan
2026-07-13
Recruiting
RemeGen Co., Ltd.
Phase 1/2
326
Hunan, Sichuan, Fujian, Guangdong, Guizhou, Heilongjiang, Changsha, Nanjing
2026-04-27
Recruiting
Ipsen
Observational
20
Beijing, Chongqing, Hunan, Nanjing, Shanghai, Xiamen
2026-04-16
Recruiting
Efficacy of Montelukast on STEMl Patients
NCT07320625Myocardial Infarction (MI)
DrugMontelukast
Shanghai Zhongshan Hospital
Phase 3
512
Dalian, Shanghai, Fuzhou, Guangdong, Ha’erbin, Hefei, Hunan, Shenyang
2026-02-01
Recruiting
Shenzhen Majory Biotechnology Co., Ltd.
Phase 1/2
42
Beijing, Hubei, Hunan
2026-01-29
Not yet open
Osteoporotic Vertebral Compression Fracture Cohort Study
NCT07321795OVCF Database, Cohort Study
Wangjing Hospital, China Academy of Chinese Medical Sciences
Observational
200
Hunan, Suzhou, Weihai, Beijing
2026-01-10
Not yet open
Hongying Jiang, MD
Not applicable
500
Beijing, Hunan, Guangxi, Jilin City, Henan
2026-01-01
Not yet open
The Third Xiangya Hospital of Central South University
Early Phase 1
13
Hunan
2025-11
Recruiting
Changhai Hospital
Not applicable
1,250
Baotou, Beijing, Hangzhou, Hunan, Lanzhou, Shandong, Shanghai, Yunnan
2025-10-13
Recruiting
Capital Medical University
Not applicable
300
Hunan, Guangxi, Beijing, Jilin City, Henan
2025-10-01
Active, closed
Shanghai Henlius Biotech
Phase 1
174
Hefei, Wuhu, Beijing, Hunan, Fuzhou, Xiamen, Lanzhou, Cangzhou
2025-09-26
Recruiting
BioNTech SE
Phase 1/2
375
Beijing, Hefei, Henan, Hunan, Shandong, Shanghai, Sichuan, Zhejiang
2025-08-27
Recruiting
Chengdu CoenBiotech Co., Ltd
Phase 3
1,784
Beijing, Hunan, Liuzhou, Xinxiang, Wuhan, Yichang, Chengdu
2025-08-09
Recruiting
Evidence-based Practice in the Management of Gastric Tube Placement in Children
NCT07038538Hospitalized Children, Nursing, Enteral Nutrition Therapy
Children's Hospital of Fudan University
Not applicable
2,750
Shanghai, Beijing, Chongqing, Gansu, Guangdong, Hefei, Henan, Hunan
2025-06-26
Recruiting
Shanghai Henlius Biotech
Phase 2
90
Hunan
2025-03-03
Recruiting
Shanghai Henlius Biotech
Phase 1/2
105
Hunan, Jinan, Chongqing
2025-02-25
Not yet open
Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)
NCT06802848Plaque Psoriasis, Psoriatic Arthritis, Scalp Psoriasis, Nail Psoriasis
DrugXeligekimab
Chongqing Genrix Biopharmaceutical Co., Ltd
Observational
1,000
Hunan
2025-01-30
Recruiting
Carbon Nanoparticle-Loaded Iron in the Treatment of Advanced Solid Tumor
NCT07433283Tumor, Solid, Lung Cancer, Pancreas Cancer, Thyroid Cancer
Sichuan Enray Pharmaceutical Sciences Company
Phase 1/2
54
Beijing, Hunan, Chongqing, Fuzhou, Haikou, Heilongjiang, Shanghai, Chengdu
2024-11-12
Active, closed
Daiichi Sankyo
Phase 1
210
Beijing, Guangzhou, Heilongjiang, Hunan, Jilin City, Shandong
2024-02-22
Recruiting
MediLink Therapeutics (Suzhou) Co., Ltd.
Phase 2
100
Hefei, Beijing, Hunan, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan
2024-02-22
Active, closed
A Study of ADRX-0706 in Select Advanced Solid Tumors
NCT06036121Solid Tumors, Triple Negative Breast Cancer (TNBC), Urothelial Cancer, Cervical Cancer
Adcentrx Therapeutics
Phase 1
144
Beijing, Fujian, Guangzhou, Hunan, Jinan, Shanghai, Wuhan
2023-09-26
Recruiting
Xiangya Hospital of Central South University
Observational
5,000
Hunan
2022-11-01
Recruiting
Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast Cancer
NCT05430399Breast Neoplasms, Locally Advanced or Metastatic Breast Cancer
DrugsUtidelone·Docetaxel
Sun Yat-sen University
Phase 3
349
Guangzhou, Hunan
2022-06-21
Recruiting
Advenchen Laboratories, LLC
Phase 1/2
228
Beijing, Hunan, Fuzhou, Shantou, Shaoguan, Guilin, Liuzhou, Nanning
2021-10-26
Active, closed
AstraZeneca
Phase 3
110
Beijing, Chongqing, Guangzhou, Guizhou, Henan, Hubei, Hunan, Jilin City
2021-06-24
Active, closed
Myasthenia Gravis Inebilizumab Trial
NCT04524273Myasthenia Gravis
DrugInebilizumab
Amgen
Phase 3
238
Beijing, Guiyang, Hunan, Jinan, Shanghai, Suzhou, Tianjin, Xi'an
2020-10-15
Active, closed
Astellas Pharma Global Development, Inc.
Phase 2
900
Hubei, Hunan, Nanjing
2016-12-22
Rows per page Showing 1–32 of 32
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 November 2026. https://priyalifescience.com/clinical-trials-china/city/hunan

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,212 studies in total at the last sync on 10 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 32 of those studies with a site in Hunan.

How many clinical trials are recruiting in Hunan?

19 of the 32 studies on this page are recruiting new participants as of the 10 Nov 2026, 03:17 UTC sync. A further 7 have not yet opened recruitment, 6 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Hunan), 32 studies
PhaseStudiesRecruitingShare
Phase 38425%
Phase 1/27621.9%
Not applicable5415.6%
Observational4212.5%
Phase 1309.4%
Phase 2329.4%
Early Phase 1103.1%
Phase 2/3113.1%

Most active sponsors

Lead sponsors with the most studies (Hunan)
Lead sponsorStudiesRecruiting
Shanghai Henlius Biotech32
Brise Pharmaceuticals Co., Ltd.21
RemeGen Co., Ltd.21
Adcentrx Therapeutics10
Advenchen Laboratories, LLC11
Amgen10
Astellas Pharma Global Development, Inc.10
AstraZeneca10
Beijing BeneWill Technology Development Co., Ltd11
BioNTech SE11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.